In the present study, we analyze the efficacy of prophylaxis with meropenem in patients receiving a matched related donor allogeneic transplant. In total, 38 patients were sequentially treated with meropenem starting on the day of the first febrile episode (n ¼ 17, group A) vs prophylactic meropenem starting on the first day with o500/mm 3 granulocytes (n ¼ 21, group B), and maintained until resolution of fever or after granulocyte count 4500/mm 3 . Of these, 16 (94%) patients in group A developed fever as compared to 16 (76%) in group B (P ¼ 0.02). While only one patient in group A did not require first-line antibiotherapy, there were seven (33%) in group B who did not require it (P ¼ 0.01) since fever lasted less than 72 h. In addition, 52% patients in group B did not require second-line antibiotics as compared to 11% among patients in group A (P ¼ 0.04). In multivariate analysis prophylaxis with meropenem (HR ¼ 2.83, 95% CI (1-8.02); P ¼ 0.04) and disease status at transplant (HR for early stage ¼ 0.15, 95% CI (0.04-0.62); P ¼ 0.04) significantly influenced the development of fever. In conclusion, the current pilot study suggests that the use of prophylaxis with meropenem during the period of neutropenia in patients undergoing allogeneic transplantation favorably affects the morbidity of the procedure by reducing febrile episodes.
prophylaxis Bacterial infections remain one of the main causes of morbidity and mortality in patients with hematological malignancies. Different strategies, such as barrier nursing, intravenous immunoglobulins, hematopoietic growth factors and antimicrobial agents, [1] [2] [3] [4] have been proposed in order to decrease infectious episodes among patients receiving intensive chemotherapy. The use of recombinant hematopoietic growth factors has shortened the duration of granulocytopenia and lessened the risk for infection, 5 but there is conflicting evidence concerning the efficacy of these growth factors in preventing infection-related mortality in stem cell transplanted patients. [6] [7] [8] In the case of antimicrobial agents, selective gut decontamination has decreased both the incidence of Gram-negative bacterial infections in neutropenic patients and the risk of acute graft-versus-host disease (aGVHD) 3, 4 and, in addition, several randomized controlled trials have demonstrated a reduction of infections caused by Gram-negative bacteria by using quinolone prophylaxis in neutropenic patients. [9] [10] [11] [12] [13] [14] [15] [16] Nevertheless, the effect of antibiotic prophylaxis on clinical outcome remains controversial with respect to the occurrence of Grampositive bacterial infections, [14] [15] [16] clinically documented infections 10 and death. 15, 16 Furthermore, some studies have reported an increased risk for developing infections with resistant bacteria [17] [18] [19] [20] [21] [22] [23] among patients receiving quinolone prophylaxis.
In addition to these conflictive findings, information regarding the use of prophylaxis antibiotics among patients undergoing allogeneic hematopoietic stem cell transplantation is scanty. [24] [25] [26] [27] In clinical practice, this situation has led to very different approaches among BMT centers.
In the present pilot study, we have analyzed the efficacy of prophylaxis with meropenem in patients receiving a matched related donor allogeneic transplant. One cohort of patients started meropenem on the first day with a granulocyte count o500/mm 3 while the second cohort received it on the day of the first febrile episode.
Patients and methods

Patients' characteristics, antimicrobial regimen and transplantation procedure
In total, 38 patients undergoing matched related donor allogeneic transplantation at our institution were sequentially treated with meropenem (1 g q8h) starting on the day of the first febrile episode (n ¼ 17, group A) vs prophylactic meropenem (1 g q8h) starting on the first day with a granulocyte count o500/mm 3 (n ¼ 21, group B), and maintained until resolution of fever or after granulocyte count 4500/mm 3 in both groups. All patients received cotrimoxazol (960 mg q12h p.o.) as prophylaxis against Pneumocystis carinii from day À9 to day À2 and then restarted once granulocyte counts reached 4500/mm 3 for 3 consecutive days until day þ 180 post transplant. In addition, HSV-positive patients received acyclovir 800 mg q12h p.o. at least up until day þ 30 and fluconazol (400 mg qd p.o.) or itraconazol (2.5 mg/kg q12h p.o.) at least up to day þ 75 after transplantation. In the event of fever lasting more than 72 h after the initial treatment, patients received vancomycin or teicoplanin in case of Gram-positive infection or amikacin or ciprofloxacyn in case of Gramnegative infection. Second-line antibiotherapy was also started according to clinical criteria (ie based on the site of infection). At 5-7 days after the first fever episode patients received antifungal treatment with conventional or liposomal amphotericin B.
Patients' characteristics are specified in Table 1 . All patients received myeloablative-conditioning regimens based on busulphan and cyclophosphamide (n ¼ 22), cyclophosphamide and TBI (n ¼ 10) or other regimens (n ¼ 6). In all patients, GVHD prophylaxis consisted of cyclosporine A (CsA) 1.5 mg/kg q12h i.v. starting on day À7 and switched to an oral dose as soon as the patient could tolerate oral medication. In the absence of grade II or more acute GVHD, CsA was tapered 5% weekly starting day þ 50 and discontinued by day þ 180. CsA levels were monitored starting day þ 1 and were maintained in the therapeutic range (150-300 ng/ml) until tapering. MTX was given at a dose of 15 mg/m 2 i.v. on day þ 1 and 10 mg/m 2 i.v. on day þ 3, þ 6 and þ 11 followed by folinic acid rescue. Disease status at transplant was categorized as early in 22 cases (acute leukemia or poor-risk myelodysplasia in first complete remission, untreated low-risk myelodysplasia, first chronic-phase CML, lymphoid malignancy in first remission), intermediate in 10 patients (acute leukemia or myelodysplasia in second or higher complete remission, second chronic-phase CML, lymphoid malignancy in second or higher complete remission or partial response) and advanced in six cases (refractory or relapsed disease).
A Hickman catheter was inserted about 2 weeks before transplant and all patients were nursed in single rooms supplied with filtered air under positive pressure or laminar air flow. Hand washing by staff and care providers and conventional preventive strategies were performed with all patients.
No differences were observed between either subgroup of patients in terms of disease status, diagnosis, age, conditioning regimen or CMV serology. Hematopoietic stem cell source was bone marrow in three and four patients from groups A and B, respectively and peripheral blood in 14 and 17 patients from groups A and B, respectively; no differences were observed between either subgroup of patients.
Assessments
Patients were examined daily for symptoms and signs of infection. Body temperature was recorded at least four times daily and more often if clinically indicated. In the event of fever, blood cultures from a peripheral vein and from Hickman catheter were taken together with any other clinically relevant cultures. A febrile episode was defined as an oral temperature above 381C for 2 h or more or a single temperature above 38.51C. Response to antibiotherapy was defined as temperature o37.51C at 72 h after commencement of therapy.
According to the EORTC criteria, infections were classified into four categories based on clinical findings, course of the febrile episode and microbiological data.
Microbiologically documented refers to a febrile episode accompanied by definite clinical signs and symptoms of infection plus microbiological confirmation from the original site (MDI: microbiologically documented infection). Bacteremia was defined as the occurrence of one positive blood culture specimen of Gram-negative organisms or Staphylococcus aureus or more than one positive culture for other Gram-positive bacteria. Clinically documented infection refers to a febrile episode accompanied by definite clinical signs and symptoms of infection but without specific microbiological proof. Unexplained fever refers to a febrile episode accompanied by equivocal signs and symptoms of infection without microbiological proof.
Statistical analysis
The influence of the different variables on fever, antibiotic requirements and infectious episodes was analyzed by nonparametric Mann-Whitney test and multiple linear regression. Other quantitative end points (number of antibiotics, antibiotic day, neutropenic days) were analyzed with the two-sample Wilcoxon test. Qualitative parameters were analyzed using w 2 test. The time to development of fever was evaluated using a Kaplan-Meier curve and the log-rank test. Significant factors were included in a multivariate analysis using a forward stepwise Cox proportional hazards regression model. Significance levels were set at 0.05. 
Results
Post transplant outcome and noninfectious toxicity
Projected overall and event-free survival at 5 years were 57 and 51%. With a median follow-up of 548 days (47-2172 days), 15 (39%) patients have died, seven (18%) due to transplant-related mortality (TRM) and eight due to disease progression. Two out of the seven patients who died due to TRM developed bacterial (Acinetobacter lwoffi) and fungal infections that led to death. No significant differences were observed between patients receiving or not prophylaxis with meropenem in terms of early and overall TRM.
Regarding hematological toxicity, all evaluable patients except one reached 40.5 Â 10 9 /l granulocytes at a median of 16 day (range: 10-32) and 420 Â 10 9 /l platelets at a median of 12 days (range: 7-56 days). No significant differences in terms of hematological toxicity were observed between patients receiving (group B) and those not receiving (group A) prophylactic meropenem.
As far as grades 3-4 extra-hematological toxicity was concerned, 10% of patients developed liver toxicity, 63% mucositis, 10% nausea/vomiting, 3% neurologic toxicity, 10% diarrhea and 3% renal toxicity. Actuarial incidence of grades II-IV aGVHD was 50% and overall and extensive chronic GVHD was 70 and 55%, respectively. No significant differences in terms of extra-hematological toxicity were observed between the two subgroups of patients.
Infectious toxicity
Concerning infectious episodes, 16 (94%) out of 17 patients included in the group A developed fever in the early post transplant period as compared to 16 (76%) among patients in group B (log rank, P ¼ 0.02; Figure 1 ). The mean number of days of fever did not differ between the two subgroups (6 days in each arm). While only one patient did not require first-line therapy with broad spectrum antibiotics in group A, there were seven (33%) patients in group B who did not require modified antibiotherapy (P ¼ 0.01) since fever lasted less than 72 h and, more importantly, 11 (52%) patients in group B did not require a second line of antibiotics as compared to two (11%) of patients included in group A (P ¼ 0.04).
As far as antibiotics were concerned, as previously specified, patients in group B received meropenem starting on the first day with a granulocyte count o500/mm 3 . Overall, median day to reach o500/mm 3 granulocytes was day þ 2 after infusion (range: 0-4 days) while patients in group A received meropenem starting on the day of the first febrile episode, which occurred at a median of 7 days after transplant (range: 0-20). Nevertheless, due to the lower incidence of both febrile episodes and the need for secondline therapy, patients in group A received a mean of 18 days (s.d. ¼ 10 days) of antibiotics as compared to 15 days (s.d. ¼ 13 days) among those patients included in group B (P ¼ 0.43). In addition, the use of empirical antifungal therapy did not differ between the two subgroups (35 and 33% received the therapy in groups A and B, respectively). Finally, the mean days of hospital stay were 35 and 32 days for groups A and B, respectively (P ¼ 0.4).
Disease status at transplant also significantly influenced the development of febrile episodes (73% of patients in early stage developed fever as compared to 100% among patients with intermediate or advanced disease status, Po0.001). Other variables such as progenitor cell source, sex, CMV serology, GVHD or conditioning regimen did not significantly influence the development of febrile episodes ( Table 2 ). The median days of neutropenia were 16 days among patients whether or not they developed any febrile episode. All variables with a 'P'-value o0.1 were included in a multivariate analysis and both antibiotic prophylaxis (HR for those not receiving prophylaxis ¼ 2.83, Infections were microbiologically documented in 12 patients (six cases from each group). In nine patients, Gram-positive bacteremias were documented and in five of them methicillin-resistant staphylococci were isolated. All five of these cases corresponded to the nonprophylaxis arm while in the remaining four patients (two from each group) non-methicillin-resistant staphylococci were isolated. In three cases, Gram-negative microorganisms were isolated: Escherichia coli documented in a urine culture in a patient included in group A and A. lwoffi documented in blood culture in two patients included in group B. Interestingly, in one of these patients, bacteremia occurred after engraftment and meropenem had already been discontinued, while in the second patient included in group B bacteremia occurred before stem cell infusion. Interestingly, the microorganism was sensitive to meropenem in both cases.
Concerning the two patients who died specifically due to infectious toxicity, one of them, included in group B, had developed a bacteremia (A. lwoffi) while off meropenem and the other patient, included in group A, died due to a fungal infection.
Discussion
Information regarding the use of antibiotic prophylaxis in the early post transplant period among patients receiving allogeneic transplantation is scanty and controversial. In fact, most data refer to small subsets of transplanted patients included within large series of cancer patients undergoing conventional chemotherapy. In previous studies, patients receiving quinolone prophylaxis had a 35% reduction in MDIs and 46% decrease in total infections as compared to those who did not receive prophylaxis. [12] [13] [14] [15] [16] In the few trials performed in bone marrow recipients, [24] [25] [26] [27] oral quinolones effectively prevented Gram-negative infections and delayed febrile episodes, thus suggesting a positive impact on outcome through antibiotic prophylaxis.
Nevertheless, several problems have emerged from the use of quinolone prophylaxis. First of all, an elevated risk for Gram-positive infections has been noted in several trials. 19 Furthermore, a major concern is that quinolone prophylaxis may increase the risk for developing infections with resistant bacteria as reported in several studies carried out in patients treated with conventional chemotherapy, 17, 18, [20] [21] [22] [23] which showed that patients receiving fluoroquinolone prophylaxis rapidly become colonized with quinolone-resistant E. coli and coagulase-negative staphylococci. In this sense, two oncology units who gave quinolone prophylaxis have documented the nosocomial spread of fluoroquinolone-resistant coagulase-negative staphylococci. 19, 28, 29 The addition of penicillin or roxithromicin to the fluorquinolone can reduce the risk of streptococcal infection. 30, 31 However, resistance to penicillin is emerging. 32 Moreover, three trials have failed to demonstrate any difference in febrile episodes using quinolone prophylaxis. 15, 33 Carbapenems have a wide spectrum of activity including Gram-positive bacteria such as Streptococci viridans, Gram-negative bacteria including Pseudomonas aeruginosa and anaerobic bacteria. This wide spectrum of activity and their low range of toxicity supports the use of these antibiotics in the allogeneic transplant setting. Meropenem used as monotherapy in neutropenic patients has shown a similar efficacy as compared to combined therapy. In the present study, we have evaluated the efficacy of antibiotic prophylaxis with meropenem started on the first day with a granulocyte count o500/mm 3 after matched related donor stem cell transplantation, and we have observed that with this approach a significant proportion of patients do not develop fever during the early post trasplant period. While previous studies performed in bone marrow recipients [24] [25] [26] [27] have only shown a delay in febrile episodes by using quinolone prophylaxis, the present study shows both a significant delay and reduction of febrile episodes.
An important issue regarding the prophylactic use of antibiotics in the allogeneic transplant setting is the emergence of widespread antibiotic resistance, and different guidelines have been proposed to minimize this risk. 34 Interestingly, in our study, no meropenem-resistant bacteria has been isolated, suggesting that to start prophylaxis only when granulocyte counts are o500/mm 3 , that is, during the period of higher risk of infection, minimizes the number of days of exposure to the drug and reduces the risk of developing infections with resistant bacteria, as reported in several studies using other approaches. [18] [19] [20] [21] [22] [23] Nevertheless, this approach should be monitored carefully and, in the absence of fever, meropenem should be discontinued when 4500 granulocytes/mm 3 are reached in order to minimize the days of exposure to the antibiotic and to avoid multiresistant bacteria. In addition, we have not observed an increased risk for Gram-positive infections among patients receiving prophylaxis with meropenem, nor an increased risk of fungal infections as suggested by both culture analysis and the similar number of days of antifungal therapy required for patients whether or not they received prophylaxis.
The economic impact of the procedure is another important aspect regarding the use of prophylaxis with any antibiotics. In the current study, we have confirmed that, although patients receiving prophylaxis started meropenem when granulocyte counts were o500/mm 3 (median of 2 days after transplant) and patients who did not receive it started antibiotics at a median of 7 days after transplant, those who were finally included in the prophylaxis group received antibiotics during a mean of 15 days as compared to 18 days among those included in the nonprophylaxis arm. This is mainly due to the lower incidence of febrile episodes among patients in group B and also to the higher percentage of patients in group A who required a second line of antibiotics.
In conclusion, this pilot study suggests that the use of prophylaxis with meropenem during the period of neutropenia in patients undergoing allogeneic stem cell transplantation favorably affects the morbidity of the procedure by reducing the febrile episodes without significantly increasing the risk of infection from multiresistant bacteria although further studies using PCR to evidence genetic mutations and larger number of patients would be required to confirm these results. In addition, this approach does not increase the overall costs of the procedure since it does not increase the total number of days of antibiotherapy.
